Harry joined Oxford Science Enterprises in March 2025, bringing over a decade of experience in biotechnology, AI, and venture-building.
As an Entrepreneur-in-Residence, Harry is leading the discovery and creation of a new Health Tech venture, with a particular focus on digital biology and AI.
Before joining OSE, Harry was part of the healthcare team at NVIDIA, where he led product development for Digital Biology software, across accelerated genomics and AI-driven drug discovery. He also co-founded Cambridge Cancer Genomics, a Y-Combinator-backed startup optimising cancer treatment through liquid biopsies and deep learning. The team were recognised with numerous accolades, including Forbes 30 under 30, and the Financial Times 100 Digital Champions, before exiting to Dante Labs in 2021.
Harry holds an MSci in Human Genetics from The University of Nottingham, a DPhil in Next Generation Sequencing technologies from the University of Oxford, and completed postdoctoral research in cancer bioinformatics at the University of Cambridge.
